Minerva Neurosciences Inc

Research Minerva Neurosciences Inc (NERV) on Bullrun: market cap USD 252.98M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerNERV
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 252.98M
• Financial periodFY2025
• Net income-USD 293.42M

Valuation Snapshot

latest market cap is USD 252.98M.

About Minerva Neurosciences Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Frequently asked questions

What is Minerva Neurosciences Inc's market cap?

Minerva Neurosciences Inc's market capitalization is USD 252.98M.

What does Minerva Neurosciences Inc do?

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases.